Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.
Ghent, Belgium, 10 March 2022 – Following the launch of the cluster flanders.healthTech in 2021, the first round of 14 consortia have started working on innovation projects in healthcare. The projects have received a total of EUR 4.7 million in VLAIO support from Flemish Minister of Economy and Innovation Hilde Crevits to help make a difference in the field of technology and innovation in healthcare.
Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies for diagnostic purposes instead of therapeutic ones. After being labelled with a miniscule amount of radioactive material, the antibodies can be used to show on PET/CT scans for example whether breast cancer cells have spread to the brain, or if patients with sarcoidosis are at risk of a sudden cardiac arrest. The company, founded in 2020, is currently looking for funding to bring its solutions to the market as soon as possible.
Ghent, Belgium, 10 March 2022 – Following the launch of the cluster flanders.healthTech in 2021, the first round of 14 consortia have started working on innovation projects in healthcare. The projects have received a total of EUR 4.7 million in VLAIO support from Flemish Minister of Economy and Innovation Hilde Crevits to help make a difference in the field of technology and innovation in healthcare.